Clinical & healthcare systems will be transformed by artificial intelligence and Innovative computing
In the last five years, we have seen significant developments in digital technologies for clinical diagnosis and personalised medicine. Innovative approaches are emerging to improve efficiency of healthcare systems.
Av Ketil F. Widerberg og Gupta Udatha
Oslo Cancer Cluster har engelsk som arbeidsspråk og vi har valgt å ikke oversette teksten
New development in cognitive computing, a platform based on artificial intelligence and signal processing where computers learn patterns and rules, will impact us in many areas. One is medical imaging in diagnostics, where machine learning will assist repetitive jobs and provide better and more precise diagnostics. Another is in-person and online consultations, where digitalisation will enable virtual assistants and potentially a disruption in hospital management with potential to give staff more time with patients. Health management, enabled by the internet of things (IoT) and mobile sensors, will lift lifestyle management and risk management to a new level. In drug discovery, the implementation of new tools for drug design and creation, again aided by statstics and machine learning, can inform how to optimize the vast space of potential drug combination when many drugs and many targets are available. These and similar developments, will change how clinical practice develops. Giving the right treatment to the right patient at the right time, also termed precision medicine, is indeed one of the great frontiers of medicine today. Cognitive technology may transform how treatment plans are designed and how we utilize genomics and new biomarkers to achieve precision medicine.
Data complexity in healthcare
The central dogma of the Information Technology requirement in medicine is software that can efficiently ‘read •• mine •• understand’ medical data; such as patient diagnostic information/health data, radiography images, clinical trial data, and drug combination therapy data etc. The health care system contains not only the simple text records, but also complex data ranging from graphs from the diagnosis labs to images from the radiology instruments. What if we could use image and text analytics to produce a computerised radiologist assistant which could quickly filter to clinicians/radiologists for decision support? What if computers can combine imaging data along with the rest of clinical patient data to summaries of the patients’ conditions, coincidental diagnosis, automatic triage and second opinion, as well as statistical comparisons to similar patients? IT companies see this need and collaborate with academia . One example is Intel, a technology company, with a Health and Life Sciences division to power the data set management and analytic tools for the optimisation of diagnostics, treatment and care delivery  . Another example is IBM’s Medical Sieve, a cognitive radiologist assistant with advanced multimodal analytics, clinical knowledge and reasoning capabilities , [5, 6].
Artificial intelligence will facilitate introduction of Personalised Medicine
Personalised Medicine is an emerging approach for disease treatment and prev- ention that takes into account individual variability in genes, environment, and lifestyle for each person . Computational systems can eventually offer patients with a fast and efficient healthcare sys- tem for both diagnosis and treatment.
One example where computational systems play a central part is the Cancer Moonshot initiative in the United States, called by President Obama in his 2016 State of the Union Address , aiming to eliminate cancer to achieve a decade’s worth of progress in 5 years. The collaboration between Lawrence Livermore National Laboratory and Norwegian Cancer Registry is a part of this strategy . The project, facilitated by Oslo Cancer Cluster, is aiming to optimize cancer screening by using machine learning and neural networks to look at historical data .
Computer-aided diagnosis methods have recently become a part of the routine clinical work with the help of emerging digital assistant technologies . Digital assistant technologies for efficient and faster diagnosis towards disease prevention – anticipating a world where diseases are minimized or avoided entirely. The penetration of IT into healthcare also helps to reduce medication errors and streamline infection-prevention protocols . One example is when sensors capture measurements when a tumor flares up again after treatment at an early stage. Another is to improve prevention by insights to minimize the risks based on learning from larger groups.Thanks to analytics, interoperability and latest technological innovations  – major tech players are getting involved in the digital health race and more companies are investing on how to integrate smart sensors, connected devices and digital assistants into diagnostic labs and clinics.
IBM Watson, a cognitive computing platform, is one example. It uses natural language processing and machine learning to reveal insights from large amounts of unstructured data . The system, analyses high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers.
Norway should take a clear position in digital health
A decade ago none of us could have imagined that the mobile technology can create a database with the wisdom of our own body. Just from a smart watch, data ranging from blood pressure to heartbeat can be recorded on a real-time basis and data of an individual can be monitored on a long term basis. This kind of patient generated data can be obtained easily and longitudinally, over the course of a lifetime, creating the concept of ‘long data’ . This comes on top the ‘big data’ concept that gained popularity with the advancement of genomic, proteomic and diagnostic technologies in clinical practice.
Apple recently announced that their ResearchKit apps can now import a user’s genetic data from the consumer testing service 23andMe. MyHeartCounts, a cardiovascular-disease app developed by Stanford University, will be the first to be able to easily incorporate users’ 23andMe data, if participants allow it . Microsoft’s Connected Health Platform is a complex platform of tools, accelerators, solutions, prescriptive architecture, designs and deployment guidance for the digital health partners .
With the advancements in both hardware and sectors, the list of such emerging technologies in the field of diagnosis and health care treatment is long. At Oslo Cancer Cluster (OCC), we understand the importance to create and encourage the latest trending technologies and establish an upper edge in digital health for faster accurate disease diagnosis and personalised medicine. Supporting governmental initiatives and infrastructure will be critical towards establishing a transparent digital health society and shaping sustainable healthcare. •
Oslo Cancer Cluster goes digital;
OCC collaborations like, the project on Computing Applications for Individualized Cancer Control Programs: Cervical Cancer Screening together with Lawrence Livermore National Laboratory ; the IBM Watson Innovation Centre incubator collaboration focusing on cognitive technology in cancer diagnostics  and the IKTPLUSS Lighthouse Project on BIG data MEDical solution (BIGMED). The latter aims to address the analytic bottlenecks for the implementation of precision medicine . OCC is part of the DoMore! project which addresses the significant problem in pathology i.e., heterogeneity in cancer; another IKTPLUSS Lighthouse Project supported by the Norwegian Research Council . OCC recently started a H2020 project «PERMIDES» with a goal of combining the technologies from biopharma and IT industry for the benefit of patient community. This EU project with the sounding name «Personalised Medicine Innovation through Digital Enterprise Solutions: PERMIDES» will utilize digital tools and novel solutions from the IT sector to support the development of new cancer treatments .
Biographical notes on authors
Ketil F. Widerberg, MBA, is General Manager of Oslo Cancer Cluster. He builds on a long experience in realizing new projects within oncology in the biopharmaceutical company Photocure ASA in collaboration with academic institutions and international commercial partners. Ketil knows big data integration/analytics through projects and transactions in the global software companies KSD Software and Descartes (DSG). Widerberg`s educational background spans from preclinical medical school to management studies. He also holds a MBA in economics/finance from the University of Cambridge. Ketil is the Chairman of Oslo Cancer Cluster Incubator. D.B.R.K. Gupta Udatha, PhD, is the Project Manager at Oslo Cancer Cluster. Gupta Udatha received doctoral degree from Chalmers University of Technology – Sweden. He has led the development of multi-national collaborations and coordinated research groups in academia & industry. Dr. Udatha has 10 years’ of R&D experience in the fields of bioinformatics, systems biology and big data analytics of biopharmaceutical data. He is also an entrepreneur and supporter of open-access publishing. He serves as the Publisher and Journal Manager of the Computational and Structural Biotechnology Journal. In addition, he is the Board Member of the Open Communications Press, which was formed by a team of academic researchers who believe in a more transparent and open system of academic publishing.
- Fiber, L., Medical Imaging Leaders Tap IBM and Watson to Tackle Cancer, Diabetes, Eye Health, Brain Disease and Heart Disease. http://www-03.ibm.com/press/us/en/pressrelease/49985.wss, 2016.
- Intel Health and Life Sciences http://www.intel.co.uk/content/www/uk/en/healthcare-it/healthcare-overview.html.
- Davis, J., Can Big Data Help Cure Cancer? InformationWeek, 2016. http://www.informationweek.com/big-data/big-data- analytics/can-big-data-help-cure-cancer-/d/d-id/1326295.
- Medical Sieve. http://researcher.watson.ibm.com/researcher/view_group.php?id=4384.
- Syeda-Mahmood, T., IBM Research. http://researcher.watson.ibm.com/researcher/view_group_pubs.php?grp=4384.
- Ridley, E.L., IBM’s bid for Merge shows allure of imaging big data. AuntMinnie, 2015. http://www.auntminnie.com/ index.aspx?sec=ser&sub=def&pag=dis&ItemID=111685.
- Investing in the National Cancer Moonshot. The White House: Office of the Press Secretary, 2016. https://www.whitehouse.gov/the-press-office/2016/02/01/fact-sheet-investing-national-cancer-moonshot.
- Jakobsen, E., VISEPRESIDENTEN I USA SER TIL NORGE. https://www.kreftregisteret.no/Generelt/Nyheter/ visepresident-ser-til-norge/, 2016.
- Joe Biden is looking to Norway. http://oslocancercluster.no/2016/09/23/joe-biden-is-looking-to-norway/, 2016.
- Doi, K., Diagnostic imaging over the last 50 years: research and development in medical imaging science and technology. Phys Med Biol, 2006. 51(13): p. R5-27.
- Bennett, C.C. and K. Hauser, Artificial intelligence framework for simulating clinical decision-making: a Markov decision process approach. Artif Intell Med, 2013. 57(1): p. 9-19.
- Hern, A., ‘Partnership on AI’ formed by Google, Facebook, Amazon, IBM and Microsoft. theguardian, 2016. https://www.theguardian.com/technology/2016/sep/28/google-facebook-amazon-ibm-microsoft-partnership-on-ai-tech-firms.
- IBM Watson. http://www.ibm.com/watson/index.html, 2016.
- Kish, L.J. and E.J. Topol, Unpatients-why patients should own their medical data. Nat Biotechnol, 2015. 33(9): p. 921-4.
- Check Hayden, E., Mobile-phone health apps deliver data bounty. Nature, 2016. 531(7595): p. 422-3.
- Microsoft: Connected Health Platform. https://www.microsoft.com/health/en-ca/ict/Pages/connected-health-platform.aspx
Fact about Oslo Cancer Cluster;
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to accelerating the development of new cancer diagnostics and medicines. We gather about 75 members from Norway and Northern Europe representing the entire oncology value chain.
As a Norwegian Centre of Expertise, the Norwegian government partially funds the cluster. An evaluation from 2013 states that Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. Major industry trends now offer a unique opportunity to strengthen the cluster’s position as a global knowledge and innovation centre.
Our members include academic research institutions, biotech companies, pharmaceutical companies, university hospitals, universities, support groups, financial institutions and regional develop- ment players in the field of cancer R&D.
Together the members work to fulfill Oslo Cancer Clusters vision: «We are committed to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.»